TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Control Trial of Complementary Food to Prevent Undernutrition Among At-Risk Infants in Fort San Michel, Haiti
Brief Summary: This randomized, controlled effectiveness study examines Nutributter programming within an integrated package of maternal and child health services offered by Haiti's Ministry of Health (MSPP) to prevent undernutrition among young children in Haiti. The aim of the process evaluation is to better understand the uptake of Nutributter® as a complementary food in the diets of young children and its feasibility and acceptability as part of MSPP's package of services. This project is being carried out at a public hospital in Fort San Michel, an impoverished community outside of Cap Haitien, Haiti.


Options:
A: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Drug: Lopinavir/ritonavir, Drug: Zidovudine, Drug: Lamivudine | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Efavirenz, Drug: Zidovudine, Drug: Lamivudine | Intervention Type: DRUG; Name: Lopinavir/ritonavir; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: Efavirenz; Assigned to Arm(s): Group B | Intervention Type: DRUG; Name: Zidovudine; Assigned to Arm(s): Group A, Group B | Intervention Type: DRUG; Name: Lamivudine; Assigned to Arm(s): Group A, Group B
B: Arm Label: Food supplement (FS); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Food supplement enriched with multiple micronutrients | Arm Label: UNIMMAP; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: UNIMMAP - multiple micronutrients | Intervention Type: DIETARY_SUPPLEMENT; Name: UNIMMAP - multiple micronutrients; Assigned to Arm(s): UNIMMAP | Intervention Type: DIETARY_SUPPLEMENT; Name: Food supplement enriched with multiple micronutrients; Assigned to Arm(s): Food supplement (FS)
C: Intervention Type: DIETARY_SUPPLEMENT; Name: fortified spread (RUTF); Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: maize and soy flour; Assigned to Arm(s): N/A
D: Arm Label: MSPP Integrated Package; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Nutributter 3 Months, Integrated Package; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Nutributter Program, Other: Integrated Package | Arm Label: Nutributter 6 Months, Integrated Package; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Nutributter Program, Other: Integrated Package | Intervention Type: DIETARY_SUPPLEMENT; Name: Nutributter Program; Assigned to Arm(s): Nutributter 3 Months, Integrated Package, Nutributter 6 Months, Integrated Package | Intervention Type: OTHER; Name: Integrated Package; Assigned to Arm(s): Nutributter 3 Months, Integrated Package, Nutributter 6 Months, Integrated Package

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Control Trial of Complementary Food to Prevent Undernutrition Among At-Risk Infants in Fort San Michel, Haiti
Brief Summary: This randomized, controlled effectiveness study examines Nutributter programming within an integrated package of maternal and child health services offered by Haiti's Ministry of Health (MSPP) to prevent undernutrition among young children in Haiti. The aim of the process evaluation is to better understand the uptake of Nutributter® as a complementary food in the diets of young children and its feasibility and acceptability as part of MSPP's package of services. This project is being carried out at a public hospital in Fort San Michel, an impoverished community outside of Cap Haitien, Haiti.


Options:
A: Arm Label: Food-for-Training component; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Food-for-Training | Arm Label: Food-for-Training + RUF (Plumpy Doz(r)); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Plumpy Doz(r) - Ready-to-Use Food, Behavioral: Food-for-Training | Intervention Type: DIETARY_SUPPLEMENT; Name: Plumpy Doz(r) - Ready-to-Use Food; Assigned to Arm(s): Food-for-Training + RUF (Plumpy Doz(r)) | Intervention Type: BEHAVIORAL; Name: Food-for-Training; Assigned to Arm(s): Food-for-Training + RUF (Plumpy Doz(r)), Food-for-Training component
B: Intervention Type: DIETARY_SUPPLEMENT; Name: PlumpyNut; Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: PlumpyDoz; Assigned to Arm(s): N/A
C: Intervention Type: DIETARY_SUPPLEMENT; Name: No food supplement; Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Food supplement: fortified spread; Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Food supplement: maize-soy flour; Assigned to Arm(s): N/A
D: Arm Label: MSPP Integrated Package; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Nutributter 3 Months, Integrated Package; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Nutributter Program, Other: Integrated Package | Arm Label: Nutributter 6 Months, Integrated Package; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Nutributter Program, Other: Integrated Package | Intervention Type: DIETARY_SUPPLEMENT; Name: Nutributter Program; Assigned to Arm(s): Nutributter 3 Months, Integrated Package, Nutributter 6 Months, Integrated Package | Intervention Type: OTHER; Name: Integrated Package; Assigned to Arm(s): Nutributter 3 Months, Integrated Package, Nutributter 6 Months, Integrated Package

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Interactive Web-based Intervention to Achieve Healthy Weight in Young Children
Brief Summary: The overall purpose of this study is to develop and implement an effective intervention program designed to prevent and treat obesity in young children.


Options:
A: Arm Label: Team PLAY Group; Type: EXPERIMENTAL; Interventions: Behavioral: Team PLAY | Arm Label: Standard Care Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Team PLAY; Assigned to Arm(s): Team PLAY Group
B: Arm Label: Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: face-to-face meetings and access to a website | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: face-to-face meetings and access to a website; Assigned to Arm(s): Intervention Group
C: Arm Label: Standard Care with Education Materials; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Care | Arm Label: Moderate Dose Motivational Interviewing; Type: EXPERIMENTAL; Interventions: Behavioral: Moderate Dose Motivational Interviewing | Arm Label: Higher Dose Motivational Interviewing; Type: EXPERIMENTAL; Interventions: Behavioral: Higher Dose Motivational Interviewing | Intervention Type: BEHAVIORAL; Name: Standard Care; Assigned to Arm(s): Standard Care with Education Materials | Intervention Type: BEHAVIORAL; Name: Moderate Dose Motivational Interviewing; Assigned to Arm(s): Moderate Dose Motivational Interviewing | Intervention Type: BEHAVIORAL; Name: Higher Dose Motivational Interviewing; Assigned to Arm(s): Higher Dose Motivational Interviewing
D: Arm Label: Intervention- Lifestyle family based; Type: EXPERIMENTAL; Interventions: Behavioral: family based lifestyle and behavioral counseling | Arm Label: Information control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: counseling focused on the child | Intervention Type: BEHAVIORAL; Name: family based lifestyle and behavioral counseling; Assigned to Arm(s): Intervention- Lifestyle family based | Intervention Type: BEHAVIORAL; Name: counseling focused on the child; Assigned to Arm(s): Information control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double Blind, Randomized, Placebo Controlled Study to Determine the Physiological Effectiveness of Januvia for Reducing Inflammation and Increasing EPC Number in HIV Infected Men and Women With Insulin Resistance and Central Adiposity.
Brief Summary: People living with human immunodeficiency virus infection (HIV) have 2-4fold greater risk for developing diabetes and heart disease than the general population. They need safe and effective treatments that reduce the risk for developing diabetes and heart disease, and improve their quality of life. This project will explore whether a new anti-diabetes medication (Januvia) with a novel mechanism of action reduces inflammation, and improves blood vessel function in HIV infected men and women with several risk factors for developing cardiovascular disease.


Options:
A: Arm Label: Exenatide first, then Placebo; Type: EXPERIMENTAL; Interventions: Drug: Exenatide, Drug: Placebo | Arm Label: Placebo first, then Exenatide; Type: EXPERIMENTAL; Interventions: Drug: Exenatide, Drug: Placebo | Intervention Type: DRUG; Name: Exenatide; Assigned to Arm(s): Exenatide first, then Placebo, Placebo first, then Exenatide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Exenatide first, then Placebo, Placebo first, then Exenatide
B: Arm Label: Sitagliptin; Type: EXPERIMENTAL; Interventions: Drug: Sitagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Sitagliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Lira 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 3.0 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Saxagliptin; Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Brief Summary: The purpose of this study is to determine effectiveness of Vyvanse compared to Concerta in adolescents with Attention-deficit/Hyperactivity Disorder (ADHD).


Options:
A: Arm Label: Methylphenidate Transdermal System (MTS); Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Transdermal System | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate Transdermal System (MTS) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: PRC-063 25 mg and Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: PRC-063 25 mg | Arm Label: PRC-063 45 mg and Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: PRC-063 45 mg | Arm Label: PRC-063 70 mg and Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: PRC-063 70 mg | Arm Label: PRC-063 85 mg and Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: PRC-063 85 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PRC-063 25 mg and Placebo, PRC-063 45 mg and Placebo, PRC-063 70 mg and Placebo, PRC-063 85 mg and Placebo, Placebo | Intervention Type: DRUG; Name: PRC-063 25 mg; Assigned to Arm(s): PRC-063 25 mg and Placebo | Intervention Type: DRUG; Name: PRC-063 45 mg; Assigned to Arm(s): PRC-063 45 mg and Placebo | Intervention Type: DRUG; Name: PRC-063 70 mg; Assigned to Arm(s): PRC-063 70 mg and Placebo | Intervention Type: DRUG; Name: PRC-063 85 mg; Assigned to Arm(s): PRC-063 85 mg and Placebo
C: Arm Label: Methylphenidate; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate | Arm Label: Matching Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Matching Placebo | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Methylphenidate | Intervention Type: OTHER; Name: Matching Placebo; Assigned to Arm(s): Matching Placebo
D: Arm Label: Lisdexamfetamine dimesylate; Type: EXPERIMENTAL; Interventions: Drug: Lisdexamfetamine dimesylate | Arm Label: Methylphenidate Hydrochloride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lisdexamfetamine dimesylate; Assigned to Arm(s): Lisdexamfetamine dimesylate | Intervention Type: DRUG; Name: Methylphenidate Hydrochloride; Assigned to Arm(s): Methylphenidate Hydrochloride | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Dose-optimization Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Brief Summary: The purpose of this study is to determine effectiveness of Vyvanse compared to Concerta in adolescents with Attention-deficit/Hyperactivity Disorder (ADHD).


Options:
A: Intervention Type: DRUG; Name: methylphenidate hydrochloride; Assigned to Arm(s): N/A
B: Arm Label: HLD200 (methylphenidate); Type: EXPERIMENTAL; Interventions: Drug: HLD200 methylphenidate hydrochloride (MPH) Capsules | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: HLD200 methylphenidate hydrochloride (MPH) Capsules; Assigned to Arm(s): HLD200 (methylphenidate) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Methylphenidate; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate | Arm Label: Matching Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Matching Placebo | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Methylphenidate | Intervention Type: OTHER; Name: Matching Placebo; Assigned to Arm(s): Matching Placebo
D: Arm Label: Lisdexamfetamine Dimesylate; Type: EXPERIMENTAL; Interventions: Drug: Lisdexamfetamine dimesylate | Arm Label: Methylphenidate Hydrochloride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lisdexamfetamine dimesylate; Assigned to Arm(s): Lisdexamfetamine Dimesylate | Intervention Type: DRUG; Name: Methylphenidate Hydrochloride; Assigned to Arm(s): Methylphenidate Hydrochloride | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Low Sodium Intake on the Anti-proteinuric Efficacy of Olmesartan in Hypertensive Patients With Albuminuria Through Open-label Randomized Trial
Brief Summary: Purpose of this study

1. Intensive education for low salt diet will be enhance the anti-proteinuric effect of Olmesartan, a popular anti-hypertensive drug of angiotensin II receptor blocker, in Koreans compared to conventional prescription of medication.
2. Intensive education for low salt diet will decrease the amount of 24 hour-urine sodium excretion compared to control group, effectively.


Options:
A: Arm Label: Low Salt Diet; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Low Salt Diet | Arm Label: Ususal Salt Diet; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Usual Salt Diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Low Salt Diet; Assigned to Arm(s): Low Salt Diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Usual Salt Diet; Assigned to Arm(s): Ususal Salt Diet
B: Arm Label: Intensive education of low salt diet; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive education of low salt diet | Arm Label: Conventional diet group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intensive education of low salt diet; Assigned to Arm(s): Intensive education of low salt diet
C: Arm Label: High risk management; Type: EXPERIMENTAL; Interventions: Behavioral: High-risk patient standardized management package | Arm Label: Salt reduction; Type: EXPERIMENTAL; Interventions: Behavioral: Community based salt reduction program | Arm Label: high risk management and salt reduction; Type: EXPERIMENTAL; Interventions: Behavioral: High-risk patient standardized management package, Behavioral: Community based salt reduction program | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: High-risk patient standardized management package; Assigned to Arm(s): High risk management, high risk management and salt reduction | Intervention Type: BEHAVIORAL; Name: Community based salt reduction program; Assigned to Arm(s): Salt reduction, high risk management and salt reduction
D: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Other: Dietary sodium restriction | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Other: Dialysate sodium concentration reduction | Arm Label: Group C; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Dietary sodium restriction; Assigned to Arm(s): Group A | Intervention Type: OTHER; Name: Dialysate sodium concentration reduction; Assigned to Arm(s): Group B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Low Sodium Intake on the Anti-proteinuric Efficacy of Olmesartan in Hypertensive Patients With Albuminuria Through Open-label Randomized Trial
Brief Summary: Purpose of this study

1. Intensive education for low salt diet will be enhance the anti-proteinuric effect of Olmesartan, a popular anti-hypertensive drug of angiotensin II receptor blocker, in Koreans compared to conventional prescription of medication.
2. Intensive education for low salt diet will decrease the amount of 24 hour-urine sodium excretion compared to control group, effectively.


Options:
A: Arm Label: High risk management; Type: EXPERIMENTAL; Interventions: Behavioral: High-risk patient standardized management package | Arm Label: Salt reduction; Type: EXPERIMENTAL; Interventions: Behavioral: Community based salt reduction program | Arm Label: high risk management and salt reduction; Type: EXPERIMENTAL; Interventions: Behavioral: High-risk patient standardized management package, Behavioral: Community based salt reduction program | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: High-risk patient standardized management package; Assigned to Arm(s): High risk management, high risk management and salt reduction | Intervention Type: BEHAVIORAL; Name: Community based salt reduction program; Assigned to Arm(s): Salt reduction, high risk management and salt reduction
B: Arm Label: Intensive education of low salt diet; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive education of low salt diet | Arm Label: Conventional diet group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intensive education of low salt diet; Assigned to Arm(s): Intensive education of low salt diet
C: Arm Label: Intervention SUBLIME; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention SUBLIME | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intervention SUBLIME; Assigned to Arm(s): Intervention SUBLIME
D: Arm Label: Diuretic treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amiloride, Drug: Hydrochlorothiazide | Arm Label: Low-sodium diet; Type: ACTIVE_COMPARATOR; Interventions: Other: Low-sodium diet | Intervention Type: DRUG; Name: Amiloride; Assigned to Arm(s): Diuretic treatment | Intervention Type: DRUG; Name: Hydrochlorothiazide; Assigned to Arm(s): Diuretic treatment | Intervention Type: OTHER; Name: Low-sodium diet; Assigned to Arm(s): Low-sodium diet

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Low Sodium Intake on the Anti-proteinuric Efficacy of Olmesartan in Hypertensive Patients With Albuminuria Through Open-label Randomized Trial
Brief Summary: Purpose of this study

1. Intensive education for low salt diet will be enhance the anti-proteinuric effect of Olmesartan, a popular anti-hypertensive drug of angiotensin II receptor blocker, in Koreans compared to conventional prescription of medication.
2. Intensive education for low salt diet will decrease the amount of 24 hour-urine sodium excretion compared to control group, effectively.


Options:
A: Arm Label: Furosemide first, then Acetazolamide; Type: EXPERIMENTAL; Interventions: Drug: Furosemide first, then Acetazolamide | Arm Label: Acetazolamide first, then Furosemide; Type: EXPERIMENTAL; Interventions: Drug: Acetazolamide first, then Furosemide | Intervention Type: DRUG; Name: Furosemide first, then Acetazolamide; Assigned to Arm(s): Furosemide first, then Acetazolamide | Intervention Type: DRUG; Name: Acetazolamide first, then Furosemide; Assigned to Arm(s): Acetazolamide first, then Furosemide
B: Arm Label: Intensive education of low salt diet; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive education of low salt diet | Arm Label: Conventional diet group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intensive education of low salt diet; Assigned to Arm(s): Intensive education of low salt diet
C: Intervention Type: BEHAVIORAL; Name: dietary intervention; Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Bardoxolone Methyl (RTA 402): 75mg; Type: EXPERIMENTAL; Interventions: Drug: Bardoxolone Methyl (RTA 402) | Arm Label: Bardoxolone Methyl (RTA 402): 150mg; Type: EXPERIMENTAL; Interventions: Drug: Bardoxolone Methyl (RTA 402) | Arm Label: Bardoxolone Methyl (RTA 402): 25mg; Type: EXPERIMENTAL; Interventions: Drug: Bardoxolone Methyl (RTA 402) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Bardoxolone Methyl (RTA 402); Assigned to Arm(s): Bardoxolone Methyl (RTA 402): 150mg, Bardoxolone Methyl (RTA 402): 25mg, Bardoxolone Methyl (RTA 402): 75mg

Answer: B